Irbesartan Teva

Irbesartan, the active ingredient in Irbesartan Teva, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to treat high blood pressure, protect kidney function in diabetes, and manage heart failure in adult patients, and improve cardiovascular outcomes as part of a comprehensive antihypertensive regimen.

GNH USA supplies Irbesartan Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and on‑time delivery across multiple regulatory regions.

Irbesartan, an angiotensin II receptor blocker, acts on the renin‑angiotensin system to lower blood pressure and protect target organs.

- Hypertension: reduces systemic vascular resistance and lowers blood pressure in patients with essential hypertension. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: improves symptoms and reduces hospitalizations in patients with chronic heart failure.

Irbesartan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Hyperkalemia: elevated blood potassium levels detectable on lab tests.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that may impair breathing. - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Renal impairment: worsening kidney function, particularly in patients with pre‑existing disease.

When prescribing Irbesartan, clinicians should consider several safety measures and patient‑specific factors.

- Monitor blood pressure: check regularly to ensure therapeutic response and avoid excessive hypotension. - Assess renal function: evaluate serum creatinine and eGFR before initiation and during therapy. - Check serum potassium: periodic testing is advised to detect hyperkalemia. - Avoid use in patients with bilateral renal artery stenosis: risk of renal failure may increase. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: concurrent use increases risk of hypotension, renal dysfunction, and hyperkalemia. - Aliskiren in diabetic patients: combined use can lead to renal impairment and hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and affect kidney function. - Lithium: increased lithium levels can cause toxicity. - Diuretics (especially thiazides): may enhance potassium loss, requiring electrolyte monitoring.